AbCellera Biologics Inc.
ABCL
$3.73
$0.092.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -47.58% | 303.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -47.58% | 303.40% | |||
| Cost of Revenue | 40.33% | -7.73% | |||
| Gross Profit | -108.20% | 42.16% | |||
| SG&A Expenses | 13.52% | 15.30% | |||
| Depreciation & Amortization | -4.08% | 2.61% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.85% | -0.34% | |||
| Operating Income | -53.83% | 20.87% | |||
| Income Before Tax | -89.21% | 31.41% | |||
| Income Tax Expenses | -620.41% | 78.04% | |||
| Earnings from Continuing Operations | -64.48% | 23.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -64.48% | 23.88% | |||
| EBIT | -53.83% | 20.87% | |||
| EBITDA | -61.02% | 23.05% | |||
| EPS Basic | -64.32% | 24.09% | |||
| Normalized Basic EPS | -88.96% | 31.56% | |||
| EPS Diluted | -59.25% | 21.67% | |||
| Normalized Diluted EPS | -88.96% | 31.56% | |||
| Average Basic Shares Outstanding | 0.12% | 0.27% | |||
| Average Diluted Shares Outstanding | 0.12% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||